NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

BSE Shares Rise 2% After Approval to Launch Derivative Contracts

On March 5, BSE shares rose 2% after the stock exchange received approval from the Securities and Exchange Board of India (SEBI) to launch derivative contracts for the BSE Sensex Next 30 index.

The BSE Sensex Next 30 index tracks the next largest and most liquid companies in the BSE 100 that are in the derivative segment and are not constituents of the BSE Sensex 30 index. BSE plans to offer cash settled monthly index futures and monthly index options, with the expiry date for the contracts set as the last Thursday of the expiry period.

At 9:27 am on March 5, BSE shares were trading 2% higher at Rs 2,674.5 apiece, aided by a gap-up opening in the market. BSE currently offers derivative contracts for the Sensex, Sensex 50, and BANKEX indices with monthly expiries.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The approval is expected to boost trading volumes and liquidity in the market. Other indices, such as the Nifty Capital Markets index, also saw gains on March 5, with MCX and Kfin Tech leading the gains by rising 2.5% and 2.3%, respectively.

Investor Takeaway

Investors should be aware of the potential for increased trading activity on the BSE Sensex Next 30 index.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.